All In Biotech

Drug Trial Radar · NCT06198712

A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

95

Planned (sponsor's estimate)

Start

Jan 12, 2023

Primary completion

Feb 23, 2028

Study completion Aug 8, 2029

Sponsor

Lead sponsor
Forma Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Novo Nordisk A/S. This study is currently undergoing a sponsor transition from Forma Therapeutics, Inc. to Novo Nordisk A/S.
First posted
Jan 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the pharmacokinetics and safety of etavopivat in paediatric participants with sickle cell disease (SCD). Participants will receive etavopivat and will be enrolled in a staggered manner, starting with the oldest age group and followed sequentially by younger cohorts after review of pharmacokinetic and safety data from the preceding cohort. All participants will undergo a 24-week primary treatment period followed by a 72-week extension treatment period to further evaluate long-term safety and pharmacokinetics of etavopivat. The total duration of the study will be approximately 96 weeks.

Conditions

  • Sickle Cell Disease

Interventions

  • EtavopivatDrug

    Participants will receive oral tablets or granules of etavopivat once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Single-dose: maximum plasma concentration (Cmax)Time frame: During the 24-week primary treatment period
  2. Single-dose: area under the plasma concentration time curve from dosing (time 0) to time t ((AUC)0-t)Time frame: During the 24-week primary treatment period
  3. Single-dose: area under the plasma concentration time curve from zero to time infinity (AUC0-inf)Time frame: During the 24-week primary treatment period
  4. Steady-state maximum plasma concentration (Cmax,ss)Time frame: During the 24-week primary treatment period
  5. Steady-state area under the concentration time curve over the dosing interval (AUCtau,ss)Time frame: During the 24-week primary treatment period
  6. Steady-state average plasma concentration (Cavg,ss)Time frame: During the 24-week primary treatment period
  7. Steady-state minimum plasma concentration (Cmin,ss)Time frame: During the 24-week primary treatment period
  8. Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs related to etavopivatTime frame: During the 24-week primary treatment period
  9. Number of premature discontinuationsTime frame: During the 24-week primary treatment period
  10. Number of dose interruptionsTime frame: During the 24-week primary treatment period
  11. Number of dose reductionsTime frame: During the 24-week primary treatment period

Locations

18 sites in 7 countries. Site status is shown where the registry gives one.

  • The Hospital for Sick Children

    Toronto, Ontario, Canada · Completed

  • HCL-HOPITAL LYON SUD_Institut d'Hématologie et d'Oncologie Pédiatrique (IHOPe)

    Lyon, France · Not yet recruiting

  • APHP - Centre de Référence des Syndromes

    Paris, France · Not yet recruiting

  • Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle

    Roeun, France · Not yet recruiting

  • KEMRI-Walter-Reed Kericho

    Kericho, Kenya · Recruiting

  • Kombewa Clinical Research Centre

    Kisumu, Kenya · Recruiting

  • Ahero Clinical Trials Unit

    Kisumu, Kenya · Recruiting

  • KEMRI CRDR Siaya Clinical Research Annex, Country Referral Hospital

    Siaya, Siaya County, Kenya · Recruiting

  • American University of Beirut Medical center

    Beirut, Lebanon · Recruiting

  • Hospital Nini

    Tripoli, Lebanon · Recruiting

  • Lagos University Teaching Hospital, Lagos

    Lagos, Nigeria · Recruiting

  • Aminu Kano Teaching Hospital (AKTH)

    Tarauni, Nigeria · Recruiting

  • University of Nigeria Teaching Hospital (UNTH)

    Ituku-Ozalla, Enugu State, Nigeria · Recruiting

  • Hacettepe University pediatric hematology

    Ankara, Turkey (Türkiye) · Completed

  • Acıbadem Adana Hastanesi

    Seyhan, Turkey (Türkiye) · Completed

  • Guys and St Thomas NHS Foundation Trust / Evelina Childrens Hospital

    London, United Kingdom · Recruiting

  • King's College Hospital - Alex Mowat Research Hub

    London, United Kingdom · Recruiting

  • Manchester Royal Infirmary_1

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.